Using network pharmacology, we identified 7 core targets of curcumol against COVID-19 and COAD, including GABRD, GABRP, BCHE, CYP3A4, PGR, HSD17B2, and SLC6A3. Here, CYP3A4 is linked to colon adenocarcinoma.